Genomics market seen hitting $84.3 billion by 2035

Market Research Future projects the global genomics market will grow from $33.5 billion in 2026 to $84.3 billion by 2035, driven by national genome programs, falling sequencing costs and broader reimbursement. The forecast points to faster adoption in clinical diagnostics, precision medicine and pharma as sequencing becomes more routine worldwide.

Why it matters: - The genomics market is moving from research-heavy use to routine clinical deployment. - Falling sequencing costs and wider payer coverage are making genomic testing more accessible in hospitals, oncology care and drug prescribing. - The forecast suggests sustained demand for sequencing instruments, consumables and bioinformatics through 2035.

What happened: - Market Research Future said the global genomics market is projected to rise from $33.5 billion in 2026 to $84.3 billion by 2035. - The forecast implies a 10.8% compound annual growth rate from 2026 to 2035. - The market base was estimated at $30.15 billion in 2025. - The report said the outlook is supported by national mega-genome programs, declining sequencing costs and broader reimbursement frameworks.

The details: - The cost to sequence a full human genome has fallen below $200, according to the report. - That compares with the original Human Genome Project’s $2.7 billion budget. - Government population genomics projects now span more than 25 nations. - Genomics England targets five million whole genomes by 2028. - The UK Biobank provides open research access to whole-genome sequencing data for all 500,000 participants and 470,000 whole exomes. - China’s National Genomics Data Center uses a 108-petabyte storage architecture tied to BGI Group’s sequencing capacity. - The 1+ Million Genomes initiative covers 24 EU member states. - India’s Genome India Project sequenced 10,074 individuals across 99 communities. - Saudi Arabia’s Genome Project aims to sequence 100,000 genomes. - Consumables were the largest product segment in 2025, with about 53.8% revenue share. - Instruments and systems were the fastest-growing product segment, at a projected 13.0% CAGR from 2026 to 2035. - Sequencing led technology with about 36.7% revenue share in 2025. - Long-read and single-molecule technologies are projected to grow at 12.8% CAGR. - Diagnostics was the largest application segment in 2025, with about 32.4% revenue share. - Precision and personalized medicine is projected to grow at 13.1% CAGR. - Drug discovery and development generated $6.85 billion in 2025. - Diagnostic and reference laboratories held the largest end-user share in 2025 at about 36.8%. - Pharmaceutical and biotechnology companies are projected to be the fastest-growing end users at 11.7% CAGR. - North America held about 38.5% of the market in 2025. - The United States accounted for about 78.2% of North American genomics revenue. - Europe was the second-largest region at $8.14 billion in 2025. - Asia-Pacific was the fastest-growing region at 13.0% CAGR. - China held about 34.5% of Asia-Pacific revenue. - The Middle East and Africa market reached $1.36 billion in 2025. - South America reached $1.66 billion in 2025. - Top five companies controlled an estimated 50% to 58% of global revenue. - Illumina held about 18% to 22% of global revenue. - Thermo Fisher Scientific held about 10% to 14% of global revenue. - Roche launched AXELIOS 1 in June 2026, a single-molecule next-generation sequencing platform using Sequencing by Expansion technology.

Between the lines: - The biggest shift is not just market growth, but where the growth is coming from. - Public genome programs and reimbursement rules are creating durable demand, not one-off research spending. - Falling sequencing costs are also widening the customer base beyond elite research centers. - The market is still concentrated, but long-read and nanopore entrants are pressuring legacy short-read leaders. - Pharma and biotech demand is rising as regulators increasingly expect companion diagnostic data in oncology submissions.

What's next: - The report expects precision multi-omic theranostics to become a central part of genomic medicine by 2030. - It projects about 40% of newly diagnosed cancer patients will undergo comprehensive genomic profiling and matched targeted therapy by 2030. - AI-integrated clinical decision support is expected to shape pharmacogenomic prescribing and testing workflows by 2028 to 2030. - As some core short-read chemistry patents expire, reagent competition could lower consumable costs by 20% to 30%. - Volume growth in Asia-Pacific and South America is expected to offset pricing pressure.

The bottom line: - Genomics is shifting from a specialized testing category to a scaled clinical infrastructure market, with public programs, payer coverage and lower costs driving the next decade of growth.